SABCS 2022

Part 2: Treamtent options in high-risk breast cancer

Part 3: Testing for TROP-2 not needed / no prognostic factor found

Part 1: Encouraging data that supports treatment decisions, but better focus on racial and social disparities is needed

Practice Changing ADC data confirmed

New insights: Are CTCs predictive or not?

SERDs - who benefits? ESR1 testing required?

New treatment perspectives in luminal breast cancer

ADC: Do we need a target? Do we need a predicitve marker?

New evidence regarding the chance of pregnancies in EBC

monarchE confirms increasing benefit. What are the real life implications?

RIGHT choice against Chemotherapy for aggressive disesase

Good news for young patients

POSITIVE-Trial shwos that temporal therapy interruption is safe and allows pregnancy

monarchE confirms data once more.

T-DXd as (neo)adjuvant treatment HR+/HER2- patients

Interruption of endocrine therapy in case of desire to have children

Benefit of extended adjuvant treatment with endocrine therapy based on genomic profiling with Mammaprint

Platin-based neoadjuvant therapy in early TNBC: impact in pCR and prognosis in younger patients

Time to reconsider Ki-67 threshold?!

Adjuvant TH confirms excellent logn-term follow-up

First trial about pregnancy in premenopausal early BC patients during their endocrinee adjuvant therapy

Chemo without benefit in node-negative disease

Abemaciclib as standard of in high-risk HR+ HER2- primary BC

Beneficio del tratamiento hormonal extendido según resultados de expresión génica con el test Mammaprint

El primer estudio sobre la gestación en pacientes con cáncer de mama precoz premenopaúsicas durante el tratamiento endocrino adyuvante

T-DXd as (neo)adjuvant treatment HR+/HER2- patients

POSITIVE-Trial dimostra che l'interruzione temporanea della terapia endocrina adiuvante è sicura e consente la gravidanza

Neoadyuvancia con carboplatino en cáncer de mama precoz y fenotipo triple negativo: impacto en RCp y pronóstico en mujeres jóvenes

SERENA-2 showed better PFS by camizestrant compared with fulvestrand

Progress in research and clinic

A shift from chemotherapy to CDK4/6

Targeted approach for endocrine responsive visceral disease

Highlights on oral SERDS in HR+ mBC

Highlights on oral SERDS in HR+ mBC

SERENA-2 ha mostrato una migliore PFS grazie a camizestrant rispetto a fulvestrant

Il miglior approccio per la malattia endocrino-responsiva con malattia viscerale

Continuing Palbociclib beyond progression does not improve PFS

Treatment alternatives to chemotherapy for visceral crisis

HR+/HER2-: Who still needs chemotherapy?

RIB + ET appears to be the better option than chemotherapy in the 1stLine even in patients with aggressive HR+/HER2- BC

De-escalation in triple positive MammaCa

Endocrine combination despite visceral crisis

Ribociclib + endocrine in high risk HR+/HER2- MBC superior to chemo

CDK4/6 inhibitors - a preferred option also for the highest risk patients

Inhibitory CDK4/6 opcją z wyboru również u chorych najwyższego ryzyka

T-DXd with so far unkown efficacy

T-Dxd - ready for prime time in the 2nd line

Important OS update for T-DXd

Robust benefit of T-Dxd confirmed with new data

Chemotherapy-free (neo)adjuvant treatment seems feasible for HR+/HER2- patients with T-DXd

Great data - as usual with T-Dxd

T-DXd new standard after pretreatment with trastuzumab and a taxane in HER2+ mBC

T-DXd as therapy of choice even after T-DM1 in HER2+ mBC

Optimal side effect management required

T-Dxd keeps us excited

Positive data for ER+ and HER2+ breast cancer

TDXd is the prefered option for pts previously treated with T-DM1

Clinically relevant and statistically significant benefit in OS and PFS with T-DXd

Beneficio clínicamente y estadísticamente significativo en OS y PFS con T-DXd

Importante actualisation des données de survie globale pour le T-DXd

Positive data for ER+ and HER2+ breast cancer

TDXd es la primera opción para pacientes tratados previamente con T-DM1

T-DXd – skuteczność, jakiej dotąd nie znaliśmy

Positive data for ER+ and HER2+ breast cancer

A new drug in the endocrine landscape

Oral SERDs are superior

oral SERDs on the rise?

Positive data for ER+ and HER2+ breast cancer

Una nouva molecola nel trattamento ormonale del tumore al seno

Une nouvelle molécule dans le traitement hormonal du cancer du sein

Pregnancies after primary breast cancer

Positive data for ER+ and HER2+ breast cancer

Estradiol withdrawal affects the micromillieu in the brain

Capivasertib - A drug for allcomers

Promising new player in the second line setting in advanced luminal BC

CTC count may help in therapy decisions

AKT inhibitor capivasertib in HR+ mBC

ADC or other therapies after CDK4/6

Olaparib as an alternative to carboplatin in aggressive HR+/HER2- mBC?

Her2-low discordance rate at 40%

Triple-positive MBC does not require chemotherapy.

CTCs with metastatic breast cancer re-visited

Le compte des CTC peut orienter la décision thérapeutique

Positive data for ER+ and HER2+ breast cancer

Capivasertib un nuovo standard per tutti?

Obiecująca nowa opcja w drugiej linii zaawansowanego, luminalnego raka piersi

HER2+ - no new approval but long-term follow up data confirm established therapies

TNBC - Practice changing data lead to new approvals - and more to come!

HR+ - Practice changing data - which therapy for which patients?

New Indications: ADCs & HER2-low

The Right Choices? CDK4/6i vs. Chemo, SERDs & ESR1?

Dealing with Brain mets / Update TNBC